bluebird bio, Inc. (BLUE)
Pre-market:
| Previous close | 0.9903 |
| Open | 0.9600 |
| Bid | 0.9619 x 400 |
| Ask | 0.9695 x 800 |
| Day's range | 0.9510 - 1.0300 |
| 52-week range | 0.8800 - 5.5300 |
| Volume | |
| Avg. volume | 8,694,561 |
| Market cap | 185.668M |
| Beta (5Y monthly) | 0.80 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.6300 |
| Earnings date | 07 May 2024 - 13 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 4.16 |
Business Wirebluebird bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SOMERVILLE, Mass., April 11, 2024--bluebird bio, Inc. (Nasdaq: BLUE) today announced that the Compensation Committee of the Company’s Board of Directors approved inducement grants of 102,700 restricted stock units ("RSUs") to twelve newly hired employees with a grant date of April 9, 2024 (the "Inducement Grants"). The Inducement Grants are subject to the terms and conditions of award agreements covering the grants and the Company’s 2021 Inducement Plan.
Insider Monkeybluebird bio, Inc. (NASDAQ:BLUE) Q4 2023 Earnings Call Transcript
bluebird bio, Inc. (NASDAQ:BLUE) Q4 2023 Earnings Call Transcript March 26, 2024 bluebird bio, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good day, and welcome to bluebird bio Fourth Quarter and 2023 Annual Results Conference Call. At this […]
Business Wirebluebird bio Reports Fourth Quarter and 2023 Annual Results and Highlights Operational Progress and 2024 Guidance
SOMERVILLE, Mass., March 26, 2024--bluebird bio, Inc. (NASDAQ: BLUE) ("bluebird bio" or the "Company") today reported fourth quarter and annual financial results and business highlights for the year ended December 31, 2023, including recent commercial and operational progress.
